Snowden Capital Advisors’s State Street SPDR S&P Biotech ETF XBI Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $1.13M | Sell |
8,850
-711
| -7% | -$88.8K | 0.03% | 494 |
|
|
2025
Q4 | $1.17M | Buy |
9,561
+4,417
| +86% | +$506K | 0.03% | 481 |
|
|
2025
Q3 | $515K | Sell |
5,144
-21
| -0.4% | -$1.89K | 0.01% | 761 |
|
|
2025
Q2 | $428K | Buy |
5,165
+323
| +7% | +$25.8K | 0.01% | 842 |
|
|
2025
Q1 | $393K | Buy |
+4,842
| New | +$433K | 0.01% | 860 |
|
|
2024
Q4 | – | Sell |
-5,099
| Closed | -$504K | – | 1270 |
|
|
2024
Q3 | $504K | Sell |
5,099
-139
| -3% | -$13.7K | 0.02% | 769 |
|
|
2024
Q2 | $486K | Sell |
5,238
-2,426
| -32% | -$218K | 0.01% | 765 |
|
|
2024
Q1 | $727K | Sell |
7,664
-423
| -5% | -$39.3K | 0.02% | 601 |
|
|
2023
Q4 | $722K | Buy |
8,087
+1,147
| +17% | +$85.2K | 0.03% | 536 |
|
|
2023
Q3 | $507K | Sell |
6,940
-648
| -9% | -$51.8K | 0.02% | 648 |
|
|
2023
Q2 | $631K | Buy |
7,588
+1,957
| +35% | +$164K | 0.02% | 626 |
|
|
2023
Q1 | $429K | Sell |
5,631
-1,849
| -25% | -$153K | 0.02% | 795 |
|
|
2022
Q4 | $621K | Buy |
7,480
+2,200
| +42% | +$178K | 0.03% | 616 |
|
|
2022
Q3 | $418K | Sell |
5,280
-1,797
| -25% | -$151K | 0.02% | 724 |
|
|
2022
Q2 | $525K | Buy |
7,077
+1,039
| +17% | +$78K | 0.02% | 606 |
|
|
2022
Q1 | $542K | Buy |
6,038
+1,721
| +40% | +$159K | 0.02% | 608 |
|
|
2021
Q4 | $483K | Sell |
4,317
-1,031
| -19% | -$124K | 0.02% | 459 |
|
|
2021
Q3 | $672K | Sell |
5,348
-220
| -4% | -$28.3K | 0.03% | 460 |
|
|
2021
Q2 | $754K | Sell |
5,568
-3,091
| -36% | -$406K | 0.04% | 436 |
|
|
2021
Q1 | $1.17M | Buy |
8,659
+69
| +0.8% | +$10.3K | 0.07% | 306 |
|
|
2020
Q4 | $1.21M | Sell |
8,590
-2,550
| -23% | -$327K | 0.08% | 279 |
|
|
2020
Q3 | $1.24M | Buy |
11,140
+4,282
| +62% | +$480K | 0.1% | 234 |
|
|
2020
Q2 | $768K | Buy |
6,858
+122
| +2% | +$12K | 0.07% | 296 |
|
|
2020
Q1 | $522K | Sell |
6,736
-2,547
| -27% | -$226K | 0.06% | 336 |
|
|
2019
Q4 | $883K | Sell |
9,283
-170
| -2% | -$14.7K | 0.08% | 291 |
|
|
2019
Q3 | $721K | Sell |
9,453
-4,169
| -31% | -$346K | 0.07% | 293 |
|
|
2019
Q2 | $1.19M | Sell |
13,622
-684
| -5% | -$58.3K | 0.12% | 230 |
|
|
2019
Q1 | $1.3M | Buy |
14,306
+3,698
| +35% | +$315K | 0.14% | 220 |
|
|
2018
Q4 | $761K | Sell |
10,608
-10,803
| -50% | -$870K | 0.1% | 261 |
|
|
2018
Q3 | $2.05M | Buy |
21,411
+258
| +1% | +$25K | 0.23% | 141 |
|
|
2018
Q2 | $2.01M | Buy |
21,153
+430
| +2% | +$39.5K | 0.26% | 120 |
|
|
2018
Q1 | $1.82M | Buy |
20,723
+712
| +4% | +$65K | 0.27% | 128 |
|
|
2017
Q4 | $1.7M | Buy |
20,011
+3,567
| +22% | +$299K | 0.24% | 138 |
|
|
2017
Q3 | $1.42M | Buy |
+16,444
| New | +$1.32M | 0.23% | 143 |
|
Other funds holding XBI
Snowden Capital Advisors's XBI Position: Q1 2026 in Review
Snowden Capital Advisors reduced its State Street SPDR S&P Biotech ETF (XBI) stake by 7.4% in Q1 2026, selling an estimated $88.8K and leaving 8,850 shares worth $1.13M. The position accounts for 0.03% of the portfolio, ranked #494.
Snowden Capital Advisors first reported a position in XBI in Q3 2017 and has held it in 34 quarters since. The position peaked at $2.05M in Q3 2018. 813 funds tracked by Wall St. Rank hold XBI as of Q1 2026.
- Snowden Capital Advisors held 8,850 shares of State Street SPDR S&P Biotech ETF worth $1.13M as of Q1 2026.
- Snowden Capital Advisors sold 711 State Street SPDR S&P Biotech ETF shares in Q1 2026, an estimated $88.8K.
- State Street SPDR S&P Biotech ETF made up 0.03% of Snowden Capital Advisors's portfolio in Q1 2026, its #494 holding.
- Snowden Capital Advisors first reported a position in State Street SPDR S&P Biotech ETF in Q3 2017 and has held it in 34 quarters since.
- Snowden Capital Advisors's State Street SPDR S&P Biotech ETF position peaked at $2.05M in Q3 2018.
- 813 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q1 2026.
Based on Snowden Capital Advisors's 13F filing for Q1 2026, filed 15 May 2026.